| . "I-Boost: An integrative boosting approach for predicting survival time with multiple genomics platforms.." Genome Biol. 2019;20(1):52. Pub Med |
| . "A framework for transcriptome-wide association studies in breast cancer in diverse study populations.." Genome Biol. 2020;21(1):42. Pub Med |
| . "CODEX2: Full-spectrum copy number variation detection by high-throughput DNA sequencing.." Genome Biol. 2018;19(1):202. Pub Med |
| . "Associating somatic mutations to clinical outcomes: a pan-cancer study of survival time.." Genome Med. 2019;11(1):37. Pub Med |
| . "Analysing breast cancer microarrays from African Americans using shrinkage-based discriminant analysis.." Hum Genomics. 2010;5(1):5-16. Pub Med |
| . "Analysis of gene-gene interactions using gene-trait similarity regression.." Hum Hered. 2014;78(1):17-26. Pub Med |
| . "Diseased region detection of longitudinal knee magnetic resonance imaging data.." IEEE Trans Med Imaging. 2015;34(9):1914-27. Pub Med |
| . "TwinMARM: Two-stage multiscale adaptive regression methods for twin neuroimaging data.." IEEE Trans Med Imaging. 2012;31(5):1100-12. Pub Med |
| . "Diseased region detection of longitudinal knee MRI data.." Inf Process Med Imaging. 2013;23():632-43. Pub Med |
| . "A longitudinal functional analysis framework for analysis of white matter tract statistics.." Inf Process Med Imaging. 2013;23():220-31. Pub Med |
| . "Performance of rapid influenza H1N1 diagnostic tests: a meta-analysis.." Influenza Other Respir Viruses. 2012;6(2):80-6. Pub Med |
| . "Using structural equation modeling to assess the links between tobacco smoke exposure, volatile organic compounds, and respiratory function for adolescents aged 6 to 18 in the United States.." Int J Environ Res Public Health. 2017;14(10):. Pub Med |
| . "Modelling recurrent events: A tutorial for analysis in epidemiology.." Int J Epidemiol. 2015;44(1):324-33. Pub Med |
| . "Predicting Alzheimer's disease using combined imaging-whole genome SNP data.." J Alzheimers Dis. 2015;46(3):695-702. Pub Med |
| . "Single-nucleotide resolution analysis of nucleotide excision repair of ribosomal DNA in humans and mice.." J Biol Chem. 2019;294(1):210-217. Pub Med |
| . "Nucleotide excision repair capacity increases during differentiation of human embryonic carcinoma cells into neurons and muscle cells.." J Biol Chem. 2019;294(15):5914-5922. Pub Med |
| . "Statistical issues and advances in cancer precision medicine research.." J Biopharm Stat. 2018;28(2):215-216. Pub Med |
| . "Medical records-based postmarketing safety evaluation of rare events with uncertain status.." J Biopharm Stat. 2013;23(1):201-12. Pub Med |
| . "Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses.." J Biopharm Stat. 2014;24(4):817-33. Pub Med |
| . "Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.." J Biopharm Stat. 2016;26(1):141-9. Pub Med |
| . "Statistical methods for conditional survival analysis. ." J Biopharm Stat. 2018;28(5):927-938. Pub Med |
| . "Medical records-based postmarketing safety evaluation of rare events with uncertain status.." J Biopharm Stat. 2013;23(4):744-55. Pub Med |
| . "Differential losses to follow-up that are outcome-dependent can vitiate a clinical trial: Simulation results.." J Biopharm Stat. 2018;28(4):633-644. Pub Med |
| . "Randomized phase II clinical trials.." J Biopharm Stat. 2014;24(4):802-16. Pub Med |
| . "On sample size calculation for comparing survival curves under general hypothesis testing.." J Biopharm Stat. 2012;22(3):485-95. Pub Med |
| . "Multivariate recurrent events in the presence of multivariate informative censoring with applications to bleeding and transfusion events in myelodysplastic syndrome.." J Biopharm Stat. 2014;24(2):429-42. Pub Med |
| . "Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups.." J Biopharm Stat. 2019;29(4):625-634. Pub Med |
| . "Practical designs for Phase I combination studies in oncology.." J Biopharm Stat. 2016;26(1):150-66. Pub Med |
| . "Optimal estimation for regression models on τ-year survival probability.." J Biopharm Stat. 2015;25(3):539-47. Pub Med |
| . "Sensitivity analysis for missing outcomes in time-to-event data with covariate adjustment.." J Biopharm Stat. 2016;26(2):269-79. Pub Med |
| . "Estimating the subgroup and testing for treatment effect in a post-hoc analysis of a clinical trial with a biomarker.." J Biopharm Stat. 2019;29(4):685-695. Pub Med |
| . "Biomarker threshold adaptive designs for survival endpoints.." J Biopharm Stat. 2018;28(6):1038-1054. Pub Med |
| . "Phase II cancer clinical trials for biomarker-guided treatments.." J Biopharm Stat. 2018;28(2):256-263. Pub Med |
| . "Optimal two-stage log-rank test for randomized phase II clinical trials.." J Biopharm Stat. 2017;27(4):639-658. Pub Med |
| . "Selection of the initial design for the two-stage continual reassessment method.." J Biopharm Stat. 2017;27(3):495-506. Pub Med |
| . "On enrichment strategies for biomarker stratified clinical trials.." J Biopharm Stat. 2018;28(2):292-308. Pub Med |
| . "Seamless phase IIa/IIb and enhanced dose-finding adaptive design.." J Biopharm Stat. 2016;26(5):912-23. Pub Med |
| . "Dose-finding designs for trials of molecularly targeted agents and immunotherapies.." J Biopharm Stat. 2017;27(3):477-494. Pub Med |
| . "The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.." J Biopharm Stat. 2015;25(1):66-88. Pub Med |
| . "Continual reassessment method with regularization in phase I clinical trials.." J Biopharm Stat. 2020;30(6):964-978. Pub Med |
| . "Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects.." J Biopharm Stat. 2017;27(6):933-944. Pub Med |
| . "Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?." J Biopharm Stat. 2017;27(3):457-476. Pub Med |
| . "A multiple imputation method for sensitivity analyses of time-to-event data with possibly informative censoring.." J Biopharm Stat. 2014;24(2):229-53. Pub Med |
| . "Enrollment and stopping rules for managing toxicity requiring long follow-up in phase II oncology trials.." J Biopharm Stat. 2015;25(6):1206-14. Pub Med |
| . "Phase II cancer clinical trials with heterogeneous patient populations.." J Biopharm Stat. 2012;22(2):312-28. Pub Med |
| . "Power and sample size calculation for microarray studies.." J Biopharm Stat. 2012;22(1):30-42. Pub Med |
| . "Sample size determination in shared frailty models for multivariate time-to-event data.." J Biopharm Stat. 2014;24(4):908-23. Pub Med |
| . "A framework for understanding cancer comparative effectiveness research data needs.." J Clin Epidemiol. 2012;65(11):1150-8. Pub Med |
| . "Basic concepts and methods for joint models of longitudinal and survival data.." J Clin Oncol. 2010;28(16):2796-801. Pub Med |
| . "Translational Breast Cancer Research Consortium (TBCRC) 022: A phase II trial of Neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases.." J Clin Oncol. 2016;34(9):945-52. Pub Med |
